On April 1, 2023, the not-for-profit corporation, Biologics Manufacturing Centre (BMC) Inc., officially assumed responsibility for the operations of the Biologics Manufacturing Centre.
This is in accordance with the Government of Canada's announcement in August 2020 that Canada's new biomanufacturing facility would be operated through a public–private partnership.
In December 2022, the National Research Council of Canada (NRC) and CCRM as founding members, set up Biologics Manufacturing Centre (BMC) Inc. as a new legal independent not-for-profit corporation to operate the Biologics Manufacturing Centre.
As an independent not-for-profit corporation, the facility will operate as a contract manufacturing organization, while delivering on its public good mandate—to respond to pandemic and other health emergency preparedness needs, support public-interest projects and contribute to the growth and resilience of Canada's life sciences sector.
Under the new legal structure, Biologics Manufacturing Centre (BMC) Inc. will be governed by its own board of directors, which will oversee the corporation and its public-good mandate.
Role of the NRC
The NRC continues to own the infrastructure, on behalf of the Government of Canada, and act as lessor of the building and equipment to the not-for-profit corporation.
The NRC is also providing annual funding to ensure the facility is maintained in a good manufacturing practices (GMP) readiness state and prepared to respond to public health emergencies.
Role of CCRM
CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies, was selected following a nation-wide open call for proposals to work with the NRC to establish the new corporation and to facilitate the transition of governance to Biologics Manufacturing Centre (BMC) Inc.
In the longer term, CCRM will continue to have an active role by providing oversight of the Biologics Manufacturing Centre both as an ongoing member of the not-for-profit corporation, and with representation on its board of directors.
To learn more about this new chapter for the Biologics Manufacturing Centre, please read: A new chapter for the Biologics Manufacturing Centre